Hospital Jerez de la Frontera

Carretera De La Ronda Circunvalacion S/n, Jerez De La Frontera, 11407, Spain

Oncology – Advanced Solid Tumors

The Hospital Jerez de la Frontera is conducting research focused on advanced solid tumors within the broader field of neoplasms. The studies aim to assess new combination therapies for safety, tolerability, and antitumor activity.

Evaluation of safety and tolerability of novel drug combinations
Identification of optimal dosing regimens through dose‑optimization studies
Assessment of antitumor efficacy in patients with advanced cancers

With a team of 42 investigators, the site is advancing precision oncology by testing the investigational agent PF‑08634404 paired with partner compounds, seeking to improve outcomes for patients across Europe.

Study of cemiplimab treatment after surgery in patients with stage II-IIIA non-small cell lung cancer who have not received chemotherapy and have PD-L1 expression of 1% or higher

Recruiting

3 1 1 1
Investigated drugs:
- Cemiplimab
+1
Olomorasib Combined With Pembrolizumab or Durvalumab in Patients With Resected or Unresectable KRAS G12C-Mutant Non-Small Cell Lung Cancer

Recruiting

3 1 1
Investigated diseases:
- Non-small cell lung cancer
Investigated drugs:
+10
A Study of Pacritinib for Reducing Bone Marrow Scarring in Patients with Myelofibrosis Who Have Low Platelet Counts

Recruiting

2 1 1
Investigated diseases:
- Myelofibrosis
Investigated drugs:
- Pacritinib
Study of ribociclib with or without chemotherapy for patients with hormone receptor positive, HER2 negative early breast cancer at intermediate risk

Recruiting

3 1 1 1
Investigated diseases:
- Hormone receptor positive HER2 negative breast cancer
Investigated drugs:
Study of Tarlatamab maintenance treatment after chemotherapy and radiation therapy in patients with limited stage small cell lung cancer who cannot receive both treatments together

Recruiting

2 1 1
Investigated diseases:
- Small cell lung cancer limited stage
Investigated drugs:
- Tarlatamab
Study of belantamab mafodotin with drug combination in adults aged 18 years and older with relapsed or refractory multiple myeloma

Recruiting

2 1 1 1
Investigated diseases:
- Plasma cell myeloma refractory
Investigated drugs:
A study to evaluate the effects of KT-621 in adults with moderate to severe eosinophilic asthma

Recruiting

2 1
Investigated diseases:
- Asthma
+2
A study of PF-08634404 and a drug combination for adult patients with extensive-stage small cell lung cancer

Recruiting

4 1 1 1
Investigated drugs:
A study of PF-08634404 and a drug combination in adults with advanced or metastatic non-small cell lung cancer

Recruiting

3 1 1
Investigated diseases:
Investigated drugs:
+2
A Study Comparing PF-08634404 and a Drug Combination with Chemotherapy in Adults with Metastatic Colorectal Cancer

Recruiting

3 1 1 1
Investigated diseases:
- Colorectal cancer metastatic
Investigated drugs:
+2